Stock listing

ASX:EMD Emyria Ltd Share Price

Home listing (ASX) of Emyria Ltd

Follow Emyria Ltd into a list and get an email when it puts out news.

Share price · ASX:EMD

$0.032 AUD 0.000 (0.0%)

Close on Nov 20, 2026

Past year -48.4% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.030 – $0.032 AUDNov 20, 2026
Volume
513,307 sharesNov 20, 2026
Market cap
$25.81M AUDAt the close on Nov 20, 2026 · price × 806.7M shares outstanding
52-week range
$0.030 – $0.070 AUDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$67,960 AUDMedian day 883,893 shares · 1 day with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
Emyria Ltd logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
ASX:EMD · Home$0.032 AUD0.000 (0.0%)513,307$0.032$0.032$0.030$0.032Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · ASX:EMD · AUD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.0320.0000.0%$0.032$0.032$0.030513,307
$0.032-0.002-5.9%$0.035$0.035$0.0302,245,134
$0.034-0.002-5.6%$0.035$0.036$0.0331,445,412
$0.036-0.001-2.7%$0.037$0.038$0.0362,904,896
$0.037-0.001-2.6%$0.037$0.038$0.037342,485
$0.038+0.001+2.7%$0.036$0.040$0.0361,319,061
$0.037+0.001+2.8%$0.036$0.038$0.036693,833
$0.0360.0000.0%$0.036$0.036$0.036473,417
$0.036-0.002-5.3%$0.038$0.038$0.036979,814
$0.038-0.002-5.0%$0.039$0.039$0.038838,183
$0.040+0.002+5.3%$0.040$0.040$0.04064,746
$0.038-0.002-5.0%$0.038$0.039$0.038232,943
$0.0400.0000.0%$0.040$0.040$0.04045
$0.040+0.001+2.6%$0.039$0.040$0.039413,341
$0.0390.0000.0%$0.039$0.040$0.0391,221,105
$0.039-0.002-4.9%$0.042$0.042$0.0391,180,167
$0.041+0.002+5.1%$0.039$0.042$0.039941,137
$0.0390.0000.0%$0.039$0.039$0.039129,884
$0.0390.0000.0%$0.039$0.039$0.0381,402,640
$0.039-0.005-11.4%$0.042$0.042$0.0373,542,687
$0.044+0.003+7.3%$0.044$0.044$0.04420,000
$0.041+0.002+5.1%$0.040$0.041$0.040340,489
$0.039-0.001-2.5%$0.040$0.040$0.0391,396,366
$0.0400.0000.0%$0.041$0.041$0.040478,700
$0.0400.0000.0%$0.040$0.041$0.0402,135,177
$0.0400.0000.0%$0.040$0.041$0.040417,433
$0.040-0.001-2.4%$0.044$0.044$0.040195,712
$0.041+0.002+5.1%$0.040$0.043$0.040499,630
$0.039-0.003-7.1%$0.042$0.042$0.0394,127,223
$0.042+0.001+2.4%$0.043$0.043$0.0411,316,919
$0.041-0.002-4.7%$0.043$0.043$0.0412,087,131
$0.043-0.002-4.4%$0.046$0.046$0.043771,249
$0.045+0.001+2.3%$0.045$0.046$0.0431,202,592
$0.044-0.001-2.2%$0.046$0.046$0.044197,603
$0.0450.0000.0%$0.045$0.045$0.045658,264
$0.045-0.001-2.2%$0.048$0.048$0.045709,919
$0.0460.0000.0%$0.047$0.047$0.046834,989
$0.046-0.001-2.1%$0.048$0.048$0.0462,790,075
$0.047-0.003-6.0%$0.050$0.050$0.0463,342,884
$0.050-0.001-2.0%$0.050$0.050$0.0492,471,183
$0.051+0.005+10.9%$0.046$0.055$0.0468,511,639
$0.046-0.002-4.2%$0.048$0.048$0.046841,527
$0.0480.0000.0%$0.049$0.050$0.048926,258
$0.048-0.002-4.0%$0.050$0.053$0.0483,637,788
$0.050+0.001+2.0%$0.047$0.050$0.047482,849
$0.0490.0000.0%$0.050$0.050$0.0462,024,263
$0.049-0.003-5.8%$0.051$0.052$0.0492,013,131
$0.052+0.005+10.6%$0.048$0.054$0.0487,941,863
$0.047-0.001-2.1%$0.047$0.048$0.047650,030
$0.0480.0000.0%$0.048$0.048$0.0471,284,797
$0.0480.0000.0%$0.048$0.050$0.0486,871,649
$0.0480.0000.0%$0.048$0.050$0.0462,274,645
$0.048+0.002+4.3%$0.046$0.048$0.0452,089,730
$0.046+0.002+4.5%$0.044$0.046$0.043514,666
$0.044-0.001-2.2%$0.045$0.045$0.044438,066
$0.0450.0000.0%$0.045$0.045$0.0450
$0.045-0.001-2.2%$0.045$0.045$0.044384,877
$0.046+0.001+2.2%$0.046$0.046$0.045284,076
$0.045-0.003-6.3%$0.049$0.049$0.0452,361,086
$0.0480.0000.0%$0.048$0.049$0.0481,098,789
$0.048+0.001+2.1%$0.047$0.048$0.0471,910,982
$0.047+0.002+4.4%$0.045$0.047$0.045808,290
$0.045-0.002-4.3%$0.048$0.049$0.0454,229,666
$0.0470.0000.0%$0.048$0.048$0.047129,403
$0.0470.0000.0%$0.047$0.048$0.044812,948
$0.047+0.003+6.8%$0.046$0.047$0.045678,010
Ticker
ASX:EMD
Asset type
Stock
Sector
Health care
Industry
Health care services
Exchange
ASX
Currency
AUD

What changed lately

Latest news

All Emyria Ltd news

Emyria Ltd on 6ix

Sector
Health care
Industry
Health care services
News releases
51 in the last 12 months · 192 in all · newest Nov 18, 2026 · oldest 2020
Decks
28 decks · latest Nov 12, 2026

Where Emyria Ltd is listed

ListingExchangeCountryCurrency
ASX:EMD · Home listing · This pageASXAustraliaAUD
Frankfurt:Q84FrankfurtGermanyEUR
OTC:EMYRFOTCUnited StatesUSD

Valuation

EV/sales 5.0× against a median of 0.5×: the highest of 11 Health care services companies shown. Statements: Year to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$19.31M AUD
P/E
Loss
EV/sales
5.0×
EV/EBITDA
Negative EBITDA
Price/book
2.9×
Gross margin
−94.3%
Operating margin
−161.6%
Net margin
−157.6%
Debt to equity
0.1×
Beta
No index for this market yet

Health care services: the 10 companies nearest in size, of 419 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Emyria Ltd · ASX:EMDUS$17.09MUS$12.78Mn/a5.0×n/a2.9×−157.6%0.1×n/a
CareView Communications, Inc. · OTC:CRVWUS$18.98MUS$17.04Mn/a1.8×36.1×n/a−29.7%n/a-0.28
Guangdong Kanghua Healthcare Group Co., Ltd. Class H · HKEX:3689US$18.84M−US$16.21M1.3×−0.1×−0.4×0.1×4.9%0.3×n/a
NeuPath Health Inc. · TSXV:NPTHUS$18.48MUS$19.65M19.7×0.3×6.1×1.1×1.5%0.2×0.08
DocGo Inc. · NASDAQ:DCGOUS$17.32M−US$1.59Mn/a−0.0×n/a0.2×−61.0%0.0×1.48
DC Healthcare Holdings Bhd · MYX:DCHCAREUS$16.97MUS$13.59M26.1×0.6×2.8×1.5×2.9%0.2×n/a
Physitrack Limited · OMXSTO:PTRKUS$16.73MUS$20.84Mn/a1.4×4.4×1.5×−57.9%0.4×n/a
Lemon Healthcare Co. · KRX:365660US$16.49MUS$880,715n/a0.1×n/a1.2×−13.2%0.0×n/a
Grand Brilliance Group Holdings Limited · HKEX:8372US$16.23MUS$9.58M15.1×0.8×8.0×1.1×8.3%0.0×n/a
EBM Technologies Incorporated · TPEX:8409US$16.02MUS$11.90M67.7×1.6×17.0×1.8×3.1%0.0×n/a
Farmaceutica Remedia SA · BVB:RMAHUS$15.37MUS$7.47M18.8×0.1×3.3×1.0×0.5%0.0×n/a
Median of the othersUS$16.85MUS$10.74M19.3×0.5×5.2×1.1×1.0%0.0×0.08

Team and board

Officers

OfficerRole
Mary-Ann RennieChief Operating Officer
Angela McGuireGeneral Manager - National Operations, Clinics
Claudia SullivanHead of Clinical Governance
Greg HutchinsonExecutive Chairman
Michael WinloExecutive Director
Tatjana HeinrichHead of Preclinical Drug Development

Board

DirectorRole
Greg HutchinsonExecutive Chairman
John TookeNon-Executive Director
Karen SmithNon-Executive Director
Michael WinloExecutive Director
Mohit KaushalNon-Executive Director

Events

QuarterResultsShare move
Q4 2025Aug 27, 2025−9.4%
Q2 2025Feb 26, 2025 · After close+3.1%
Q2 2023Feb 27, 2023 · Before open−2.3%
Q4 2022Aug 29, 2022 · After close0.0%
Q2 2022Feb 28, 2022 · Before open+5.7%
Q4 2021Aug 31, 20210.0%
Q2 2021Feb 24, 2021−7.0%

Open Events

Decks

DeckKindSlidesDate
Shareholder Meeting (November 2026)Shareholder meeting9 slidesNov 12, 2026
Q3 2026 Earnings PresentationEarnings11 slidesNov 2, 2026
FY2026 Earnings PresentationEarnings11 slidesSep 8, 2026
Investor Presentation (July 2026)Investor deck22 slidesJul 27, 2026
Corporate Update (June 2026)Corporate update24 slidesJun 11, 2026
Q1 2026 Earnings PresentationEarnings13 slidesMay 5, 2026
Ignite Investment Summit Singapore 2026Conference15 slidesApr 21, 2026
Sharewise Webinar (October 2025)Conference22 slidesOct 15, 2025
Investor Presentation (August 2025)Investor deck23 slidesAug 28, 2025
Euroz Hartleys 2025 Healthcare ForumConference24 slidesFeb 4, 2025
All 28 decks
DeckKindSlidesDate
ShareCafe Small Cap Hidden Gems Webinar 2024Conference29 slidesSep 6, 2024
ShareCafe Small Cap "Hidden Gems" Webinar (February 2024)Conference17 slidesFeb 2, 2024
ASA Virtual Investor Summit October 2023Conference24 slidesOct 27, 2023
Corporate Update (September 2023)Corporate update43 slidesSep 6, 2023
Corporate Update (July 2023)Corporate update47 slidesJul 6, 2023
Investor Presentation (March 2023)Investor deck26 slidesMar 16, 2023
Investor Presentation (February 2023)Investor deck30 slidesFeb 24, 2023
Biotech Showcase, San Francisco 2023Conference54 slidesJan 10, 2023
Investor Presentation (November 2022)Investor deck47 slidesNov 23, 2022
Investor Presentation (October 2022)Investor deck32 slidesOct 13, 2022
Investor Presentation (June 2022)Investor deck32 slidesJun 1, 2022
Investor Presentation (March 2022)Investor deck35 slidesMar 24, 2022
Hidden Gems Webinar (March 2022)Conference28 slidesMar 4, 2022
Share Café June 2021 "Hidden Gems": medicinal cannabis/hemp WebinarConference25 slidesJun 18, 2021
Shareholder Meeting (November 2020)Shareholder meeting28 slidesNov 13, 2020
Investor Presentation (October 2020)Investor deck32 slidesOct 14, 2020
Emerald Clinics — Investor Presentation (June 2020)Investor deck25 slidesJun 25, 2020
Emerald Clinics — Investor Presentation (March 2020)Investor deck23 slidesMar 5, 2020

Open Decks

Financials

Annual, in AUD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue3.88M1.39M2.20M1.59M1.82M1.98M1.01M109.9K0
Cost of revenue7.54M1.37M2.37M4.91M6.24M3.56M3.80M1.73M
Gross profit-3.66M24.5K-167.5K-3.32M-4.41M-1.58M-2.79M-1.62M
Research and development531.1K812.2K2.09M1.80M2.21M2.62M1.51M221.5K221.5K
Selling, general and administrative5.26M3.52M3.43M3.43M4.61M1.95M2.25M477.6K184.9K
Operating income-6.27M-2.65M-6.90M-7.12M-8.54M-5.71M-5.63M-2.71M-64.3K
Depreciation and amortization457.8K466.1K694.9K400.6K309.5K344.9K383.5K94.8K257.3K
EBITDA-5.81M-2.18M-6.21M-6.72M-8.23M-5.37M-5.25M-2.61M193.0K
Interest expense61.3K134.6K253.3K128.8K72.2K66.9K59.5K4.04K60
Income before tax-6.31M-3.14M-14.0M-7.22M-8.49M-4.91M-5.24M-2.68M-64.3K
Income tax-191.1K-2.53M-2.09M-1.16M5-14-120
Net income-6.11M-3.14M-11.5M-5.13M-7.33M-4.91M-5.24M-2.68M-64.3K
Earnings per share, basic-0.01-0.01-0.03-0.02-0.03-0.02-0.03-0.01-0.00

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents7.29M3.57M1.57M2.73M3.88M6.53M3.69M2.61M3.04M
Receivables794.4K19.0K30.7K85.5K87.5K273.4K121.6K59.9K19.3K
Inventory329.3K-3.41K-59.9K-19.3K
Current assets8.53M3.81M1.93M2.85M4.12M6.88M3.84M2.67M3.06M
Property, plant and equipment819.8K1.26M496.0K1.08M1.28M921.7K706.5K
Goodwill1.32M1.56M1.56M
Total assets11.5M6.62M5.43M10.2M8.25M9.06M5.06M3.52M3.06M
Accounts payable945.8K369.9K504.0K1.12M619.1K245.5K149.0K148.4K242.9K
Current liabilities1.96M801.5K2.24M3.15M1.46M1.03M1.00M272.7K250.4K
Long-term debt02.75M
Total debt787.4K613.5K1.72M1.27M632.7K949.7K610.8K3.15M
Total liabilities2.65M1.31M3.00M3.37M1.93M1.88M1.28M3.03M250.4K
Shareholders' equity8.85M5.31M2.43M6.79M6.32M7.18M3.78M499.5K2.81M
Shares outstanding739.8M448.6M359.0M289.4M268.6M220.2M173.8M195.3M195.3M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations-4.56M-2.70M-4.28M-3.77M-5.43M-3.94M-4.45M-2.59M-20.8K
Capital spending-366.2K-13.9K-159.1K-3.23M-2.03M-661.4K-201.8K-844.8K-844.8K
Free cash flow-4.92M-2.72M-4.44M-7.01M-7.46M-4.60M-4.65M-3.44M-20.8K
Cash from investing-546.6K81.1K-1.38M-3.23M-2.03M-661.4K-201.8K-901.1K-901.1K
Cash from financing8.82M4.63M4.50M5.86M4.81M7.44M5.73M3.11M3.06M
Dividends paid-62.6K-767.7K-341.8K-527.4K
Share buybacks-523.8K5.73M-139.4K-320.0K-527.5K-527.5K-742.7K03.06M
Change in cash3.72M2.00M-1.17M-1.15M-2.65M2.84M971.3K-324.4K3.04M

Open Financials

Filings

FilingDateTypeFiled with
Emyria Recruits 31 Therapists to Meet Growing Patient DemandNov 18, 2026Operations updateASX
Change of Director's Interest Notice x 2Nov 17, 2026Ownership change noticeASX
Application for quotation of securities - EMDNov 17, 2026FinancingASX
Final Director's Interest Notice - J. TookeNov 12, 2026Ownership change noticeASX
Results of Annual General MeetingNov 12, 2026Meeting outcomeASX
2026 Annual General Meeting PresentationNov 11, 2026Annual reportASX
Notification of cessation of securities - EMDNov 10, 2026FinancingASX
September 2026 Quarterly Investor Webinar PresentationNov 1, 2026Quarterly reportASX
September 2026 Quarterly Investor Update Webinar InvitationOct 29, 2026Meeting noticeASX
September 2026 Quarterly Activities Report and Appendix 4COct 28, 2026Quarterly reportASX
All 176 filings
FilingDateTypeFiled with
September 2026 Quarterly Activities Report and Appendix 4COct 28, 2026Quarterly reportASX
Annual ReportOct 8, 2026Annual reportASX
Appendix 4G and Corporate Governance StatementOct 8, 2026Other filingsASX
Letter to Shareholders - Notice of Annual General MeetingOct 8, 2026Meeting noticeASX
Notice of Annual General Meeting/Proxy FormOct 8, 2026Meeting noticeASX
Retirement of Non-Executive DirectorOct 8, 2026Management or board changeASX
Webinar with Former Secretary of Veterans Affairs Dr ShulkinOct 5, 2026Other filingsASX
Notification of cessation of securities - EMDOct 5, 2026FinancingASX
Emyria Successfully Opens First NSW Empax ClinicSep 28, 2026Other filingsASX
Application for quotation of securities - EMDSep 24, 2026FinancingASX
Former US Veterans Affairs Secretary Joins EmyriaSep 20, 2026Management or board changeASX
Emyria Presentation at FDA HearingSep 15, 2026Operations updateASX
FDA Selects EMD to Present at Psychedelic Medicines HearingSep 9, 2026Operations updateASX
Emyria Set to Launch First NSW ClinicSep 7, 2026Other filingsASX
Emyria Year End Presentation for Investor WebinarSep 7, 2026Other filingsASX
Emyria Financial Year-end Update WebinarSep 6, 2026Other filingsASX
Revised Securities Trading PolicySep 6, 2026Other filingsASX
Appendix 4E & Annual Financial Report Year End 30 June 2026Aug 31, 2026Annual reportASX
2026 Annual General Meeting - Key DatesAug 31, 2026Meeting noticeASX
Emyria Unlocks Treatment CapacityAug 19, 2026Operations updateASX
Notification of cessation of securities - EMDAug 16, 2026FinancingASX
Change of Registered Office and Principal Place of BusinessAug 9, 2026Other filingsASX
June 2026 Quarterly Activities Report and Appendix 4CJul 28, 2026Quarterly reportASX
June 2026 Quarterly Investor WebinarJul 28, 2026Meeting noticeASX
Emyria Depression Program Shows Positive ResultsJun 23, 2026ResultsASX
Emyria Confirms NSW Workforce Ahead of Clinic OpeningJun 21, 2026Other filingsASX
Emyria Company Update PresentationJun 10, 2026Operations updateASX
TGA Update to Accelerate Empax Therapist RecruitmentMay 27, 2026Operations updateASX
Emyria Activates First Victorian Empax ClinicMay 17, 2026Operations updateASX
March Quarter Investor Video PresentationMay 4, 2026Quarterly reportASX
Emyria Extends National Expansion into New South WalesApr 28, 2026Operations updateASX
March 2026 Quarterly Activities Report and Appendix 4CApr 27, 2026Quarterly reportASX
Emyria Launches Global Partnership ProgramApr 19, 2026Operations updateASX
EMD Commences NSW Workforce Recruitment To Support ExpansionApr 1, 2026Operations updateASX
Key Milestones Achieved for First Victorian Empax ClinicMar 23, 2026Operations updateASX
Appendix 4D and Half Year End Financial ReportFeb 26, 2026Interim reportASX
Medibank Expands Funding to Emyria's Victorian ClinicFeb 15, 2026Operations updateASX
Emyria's PTSD Program Delivers Lasting RecoveryFeb 1, 2026ResultsASX
December 2025 Quarterly Activities Report and Appendix 4CJan 27, 2026Quarterly reportASX
Victorian Clinic Confirmed, National Rollout ProceedingDec 15, 2025Operations updateASX
Emyria's Perth Expansion a Template for East Coast RolloutDec 10, 2025Operations updateASX
Institutional Placement Accelerates EMD National ExpansionNov 19, 2025FinancingASX
Trading HaltNov 17, 2025Trading halt or suspensionASX
September 2025 Quarterly Activities Report and Appendix 4COct 26, 2025Quarterly reportASX
Medibank Expands Funding Agreement to Emyria Brisbane ClinicOct 14, 2025Operations updateASX
Emyria Secures Medibank Funding for Depression Care ProgramSep 22, 2025Operations updateASX
Appendix 4E & Annual Report for the Year Ended 30 June 2025Aug 27, 2025Annual reportASX
Emyria to Expand Perth Clinic to Meet Growing DemandAug 26, 2025Other filingsASX
Emyria Commences National Expansion with Avive in BrisbaneJul 28, 2025Operations updateASX
June 2025 Quarterly Activities Report and Appendix 4CJul 28, 2025Quarterly reportASX
Medibank to Fund Emyria's PTSD Program at Perth ClinicJun 18, 2025Operations updateASX
PTSD Gains Sustained at 6m Follow-Up, MOU Signed with ANUMay 27, 2025ResultsASX
March 2025 Quarterly Activities Report and Appendix 4CApr 28, 2025Quarterly reportASX
Emyria Opens New Empax Centre to Meet Demand and Payer NeedsApr 13, 2025Operations updateASX
Emyria Reports Promising 3-Month PTSD Treatment ResultsFeb 3, 2025ResultsASX
December 2024 Quarterly Activities Report and Appendix 4CJan 31, 2025Quarterly reportASX
Leadership UpdatesJan 21, 2025Management or board changeASX
Emyria Secures $2.525M in Strongly Supported PlacementNov 26, 2024FinancingASX
Response to ASX Price QueryNov 12, 2024Explanation requestASX
Emyria & UWA Partner to License Novel Serotonin TherapiesOct 30, 2024Operations updateASX
September 2024 Quarterly Activities Report and Appendix 4COct 29, 2024Quarterly reportASX
Emyria Gains Ethics Endorsement for Psilocybin ProgramOct 27, 2024Operations updateASX
Emyria Shares Interim Success in PTSD Treatment ProgramSep 2, 2024ResultsASX
Appendix 4E & Annual Report for the Year Ended 30 June 2024Aug 30, 2024Annual reportASX
June 2024 Quarterly Activities Report and Appendix 4CJul 29, 2024Quarterly reportASX
Emyria, UWA Secure $499K Grant for MDMA Analogue ProgramJun 30, 2024Other filingsASX
Empax Centre Selected As Key Site In Global PTSD StudyJun 19, 2024Operations updateASX
March 2024 Quarterly Activities Report and Appendix 4CApr 25, 2024Quarterly reportASX
Emyria Receives Bids of $2.3M to Expand Clinical ServicesApr 23, 2024FinancingASX
Emyria Opens Empax Centre to Advance Mental Health CareApr 9, 2024Operations updateASX
Emyria Expands Specialist AP Team - First Female for MDMA-ATApr 4, 2024Operations updateASX
Emyria, Reach Wellness Enter MDMA-AT Research AgreementApr 2, 2024Operations updateASX
Response to ASX Aware QueryMar 12, 2024Explanation requestASX
December 2023 Quarterly Activities Report and Appendix 4CJan 30, 2024Quarterly reportASX
Emyria Receives $2.5M R&D Tax Incentive RefundJan 14, 2024ResultsASX
Emyria Specialist Granted Authorised Prescriber StatusJan 9, 2024Operations updateASX
Board Changes and Executive RestructuringNov 12, 2023Management or board changeASX
Emyria Secures Ethics Endorsement for MDMA AP ApplicationOct 29, 2023Operations updateASX
September 2023 Quarterly Activities Report and Appendix 4COct 25, 2023Quarterly reportASX
Health Canada Approval Received for MDMA ImportOct 18, 2023Operations updateASX
Emyria's Clinic Achieves Key MDMA-AT Dosing MilestoneOct 8, 2023Operations updateASX
Completion of Entitlement OfferOct 5, 2023FinancingASX
Emyria Secures Local MDMA to Start PTSD Trial DosingSep 20, 2023Other filingsASX
Emyria Completes Acquisition of the Pax CentreSep 13, 2023Acquisition or disposalASX
Strategic Update & Entitlement Offer PresentationSep 5, 2023FinancingASX
ProspectusSep 5, 2023Offer documentASX
Emyria Gets $2M Bids, Sets $3.1M Entitlement OfferSep 4, 2023FinancingASX
Appendix 4E Preliminary Financial ReportAug 30, 2023ResultsASX
Emyria Launches Ketamine-Assisted Therapy ProgramAug 7, 2023Other filingsASX
June 2023 Quarterly Activities Report and Appendix 4CJul 31, 2023Quarterly reportASX
Emyria Recruits First Patient MDMA-Assisted Therapy TrialJul 9, 2023Other filingsASX
Presentation - Pax Acquisition and Company UpdateJul 5, 2023Acquisition or disposalASX
Pax Centre Acquisition to Advance Psychedelic TherapiesJul 3, 2023Acquisition or disposalASX
Emyria Receives Ethics Approval for MDMA-assisted TherapyJun 7, 2023Other filingsASX
Emyria Completes $2.5m PlacementMay 1, 2023FinancingASX
March 2023 Quarterly Activities Report and Appendix 4CApr 28, 2023Quarterly reportASX
Emyria Unveils Highest Potency CBD Capsule for FDA PathwayApr 23, 2023Other filingsASX
Emyria to Develop Psilocybin Therapy Care ModelApr 17, 2023Other filingsASX
Emyria, Aspen Sign Binding Commercial Term Sheet for EMD-RX5Apr 3, 2023Other filingsASX
Strong Recruitment for EMD-RX5 Phase 3 TrialMar 22, 2023Other filingsASX
Emyria Grows MDMA Asset for Neuro & Mental Health TherapyMar 19, 2023Other filingsASX
Emyria partners with PAX Centre for MDMA-assisted therapyMar 6, 2023Other filingsASX
Half Yearly Report and AccountsFeb 26, 2023Interim reportASX
Emyria secures clinical-grade MDMA supply for Aust patientsFeb 12, 2023Other filingsASX
Emyria expands MDMA programs following landmark TGA decisionFeb 5, 2023Other filingsASX
Appendix 4C - QuarterlyJan 30, 2023Quarterly reportASX
First dosing commenced for pivotal EMD-RX5 Phase 3 trialJan 29, 2023Other filingsASX
Emyria receives $2.1M R&D tax incentive refundJan 11, 2023Other filingsASX
Emyria accepted into National Institutes of Health ProgramNov 27, 2022Other filingsASX
Placement completion and secondary trading noticeNov 22, 2022FinancingASX
Emyria completes $3m placementOct 30, 2022FinancingASX
Emyria and UWA expand unique MDMA-inspired analogue libraryOct 17, 2022Other filingsASX
Emyria expands clinical sites for EMD-RX5 Phase 3 trialSep 25, 2022Other filingsASX
Emyria commences US preclinical program for MDMA librarySep 19, 2022Other filingsASX
Appendix 4E and Annual ReportAug 29, 2022Annual reportASX
Positive results received for Emyrias MDMA-inspired programAug 17, 2022Other filingsASX
Emyria receives ethics approval for EMD-RX5 Phase 3 trialAug 16, 2022Other filingsASX
Preclinical studies initiated for MDMA-inspired analoguesAug 4, 2022Other filingsASX
Emyria expands drug candidate library inspired by MDMAJul 17, 2022Other filingsASX
Emyria expands MDMA analogue program with UWAMay 31, 2022Other filingsASX
EMD-RX5 demonstrates excellent safety and bioavailabilityMay 24, 2022Other filingsASX
Further positive MDMA analogue screening results receivedMay 9, 2022Other filingsASX
Emyria launches second ultra-pure CBD capsuleMar 16, 2022Other filingsASX
Recruitment commenced for EMD-RX5 Phase 1 StudyMar 8, 2022Other filingsASX
Ethics approval received for EMD-RX5 Phase 1 StudyMar 3, 2022Other filingsASX
Emyria grows its novel MDMA-analogue libraryFeb 21, 2022Other filingsASX
Phase 1 trial commences Q1, 2022 for Emyrias ultra-pure CBDJan 19, 2022Other filingsASX
Emyria adds wearables to psychedelic-assisted therapy trialsDec 19, 2021Other filingsASX
Pause in TradingDec 15, 2021Trading halt or suspensionASX
Positive animal data for Emyrias ultra-pure CBD capsuleDec 14, 2021Other filingsASX
Positive initial MDMA-analogue screening resultsDec 7, 2021Other filingsASX
Emyria receives $1,162,000 R&D Tax Incentive RefundNov 23, 2021Other filingsASX
Emyria Welcomes Tattarang as Strategic InvestorNov 21, 2021Other filingsASX
MDMA Analogue Development MilestoneOct 18, 2021Other filingsASX
Emyria selected to join Palantirs Foundry Builders ProgramOct 6, 2021Other filingsASX
Novel MDMA Analogue Screening Program AdvancedSep 21, 2021Other filingsASX
Emyria Expands Psychiatry Advisory for Psychedelics and MDMASep 15, 2021Other filingsASX
MDMA-analogues Show Promise for Parkinsons DiseaseAug 31, 2021Other filingsASX
Emyria Engages Calvert Labs for Preclinical CBD studiesAug 26, 2021Other filingsASX
Emyria Appoints Expert Neuropharmacologist for MDMA ProgramAug 19, 2021Other filingsASX
Emyria Executes Pure CBD Agreement with AltaSciencesAug 12, 2021Other filingsASX
Emyria to Develop Novel Psychedelics Pipeline with UWAAug 4, 2021Other filingsASX
Emyria Advances EMD-004 Program Towards RegistrationJun 14, 2021Other filingsASX
Emyria Data Validated, Care Model Reduces OpioidsJun 6, 2021Other filingsASX
Emyria Obtains TGA Approval for Medical Grade Monitoring AppMay 12, 2021Other filingsASX
Emyria and MMA launch MDMA-assisted therapy program for PTSDMay 4, 2021Other filingsASX
$5m Placement for Drug Registration and Treatment PipelineApr 21, 2021FinancingASX
Emyria and Cann Partner to Register CBD ProductMar 28, 2021Other filingsASX
Emyria Adds Second Clinical Site in PerthMar 1, 2021Other filingsASX
Emyria adds second Emerald Clinic in MelbourneFeb 9, 2021Other filingsASX
Emyria wins digital health monitoring grant with UWAFeb 4, 2021Other filingsASX
FDA Position on RWE to Guide RegistrationJan 26, 2021Other filingsASX
Emyria Pursuing Registration of EMD-003 in CY2021Jan 4, 2021Other filingsASX
Emyria to Benefit from Final TGA Ruling on CBD MedicinesDec 15, 2020Other filingsASX
Emyria Sees Strong Interest in IBS StudyDec 3, 2020Other filingsASX
Emyria Launches Drug Development Program Based on RWENov 24, 2020Other filingsASX
Emyria Partners with Thought Leaders in Psychedelic TherapyNov 18, 2020Other filingsASX
Emyria Enters Data Deal with ZLD to Support Autism TrialNov 8, 2020Other filingsASX
Webinar on Global Partnership with Sapphire Medical ClinicsOct 21, 2020Other filingsASX
Emyria Signs Real-World Data Agreement with ZeliraSep 29, 2020Other filingsASX
Preliminary Final Report and Full Year Statutory AccountsAug 31, 2020Annual reportASX
Emerald Clinics Successfully Raises $2.2m in PlacementAug 28, 2020FinancingASX
Record Appointments International Expansion and Name ChangeAug 13, 2020Other filingsASX
Emerald Signs RWE Contract with Canopy Growth UK CompanyAug 9, 2020Other filingsASX
EMDs Digital Health Platform Expands with New TechnologyJun 21, 2020Other filingsASX
EMD Program Manager of National Clinical Data and AnalyticsMay 11, 2020Other filingsASX

Open Filings

Cap table

Built by 6ix from Emyria Ltd’s releases

Common shares
806,686,029
Fully diluted
806,686,029

Fully diluted

LineShares
Common shares806,686,029

Share count over time

CountShares
Nov 22, 2026806,686,029

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Angela McGuireGeneral Manager - National Operations, Clinics · Since at least Nov 4, 2026
Claudia SullivanHead of Clinical Governance · Since at least Nov 4, 2026
Greg HutchinsonExecutive Chairman · Since at least Aug 13, 2025
John TookeNon-Executive Director · Since at least Oct 9, 2026
Karen SmithNon-Executive Director · Since at least Nov 5, 2026
Mary-Ann RennieChief Operating Officer · Since at least Nov 4, 2026
Michael WinloExecutive Director · Since at least Jun 18, 2025
Mohit KaushalNon-Executive Director · Since at least Nov 5, 2026
Tatjana HeinrichHead of Preclinical Drug Development · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Emyria Ltd.